{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:51:48Z","timestamp":1783007508985,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["334823"],"award-info":[{"award-number":["334823"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of a radioimmunoconjugate to locally target mesothelioma cancer cells has been proposed as a treatment. CD146, upregulated in mesothelioma but not in healthy tissues, is a promising therapeutic target. This study characterized CD146 expression and binding\/internalization kinetics of the CD146-targeting antibody OI-3 coupled with <jats:sup>212<\/jats:sup>Pb (<jats:sup>212<\/jats:sup>Pb-TCMC-OI-3) in human mesothelioma cells. Flow cytometry showed that both chimeric (chOI-3) and murine (mOI-3) antibodies rapidly bound and internalized within 1\u20136\u00a0h in MSTO-211H cells. <jats:sup>212<\/jats:sup>Pb-TCMC-chOI-3 exhibited 3.1- to 13.7-fold and 3.1- to 8.5-fold increased internalized <jats:sup>212<\/jats:sup>Pb and <jats:sup>212<\/jats:sup>Bi atoms per cell at 2 and 24\u00a0h, respectively, compared to isotype control, underscoring enhanced internalization efficiency. Intraperitoneal administration of <jats:sup>212<\/jats:sup>Pb-TCMC-mOI-3 to mice with intraperitoneal MSTO-211H xenografts improved median survival by a ratio of 1.3 compared to non-binding <jats:sup>212<\/jats:sup>Pb-TCMC-mIgG1. The ability of <jats:sup>212<\/jats:sup>Pb-TCMC-mOI-3 to target and inhibit the growth of intraperitoneal mesothelioma xenografts supports targeted radionuclide therapy\u2019s efficacy for metastatic peritoneal mesothelioma. This study highlights the potential of localized CD146-targeted radioimmunotherapy for malignant mesothelioma, offering a new avenue for improving patient outcomes.<\/jats:p>","DOI":"10.1038\/s41598-024-76778-z","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T09:12:01Z","timestamp":1730193121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma"],"prefix":"10.1038","volume":"14","author":[{"given":"Kim","family":"Lindland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion Masitsa","family":"Malenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Gong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Bj\u00f8rnlund","family":"B\u00f8nsdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"Juzeniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan M.","family":"Dragovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"76778_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim, J., Bhagwandin, S. & Labow, D. M. Malignant peritoneal mesothelioma: a review. Ann. Transl. Med. 5, 236. https:\/\/doi.org\/10.21037\/atm.2017.03.96 (2017).","journal-title":"Ann. Transl. Med."},{"key":"76778_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/1753465816628800","volume":"10","author":"S Kondola","year":"2016","unstructured":"Kondola, S., Manners, D. & Nowak, A. K. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther. Adv. Respir. Dis. 10, 275\u2013288. https:\/\/doi.org\/10.1177\/1753465816628800 (2016).","journal-title":"Ther. Adv. Respir. Dis."},{"key":"76778_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","volume":"35","author":"S Dacic","year":"2022","unstructured":"Dacic, S. Pleural mesothelioma classification-update and challenges. Mod. Pathol. 35, 51\u201356. https:\/\/doi.org\/10.1038\/s41379-021-00895-7 (2022).","journal-title":"Mod. Pathol."},{"key":"76778_CR4","doi-asserted-by":"publisher","first-page":"107440","DOI":"10.1016\/j.lungcan.2023.107440","volume":"187","author":"DW Dumoulin","year":"2024","unstructured":"Dumoulin, D. W. et al. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma. Lung Cancer 187, 107440. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107440 (2024).","journal-title":"Lung Cancer"},{"key":"76778_CR5","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/jco.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao, A. S., Wistuba, I., Roth, J. A. & Kindler, H. L. Malignant pleural mesothelioma. J. Clin. Oncol. 27, 2081\u20132090. https:\/\/doi.org\/10.1200\/jco.2008.19.8523 (2009).","journal-title":"J. Clin. Oncol."},{"key":"76778_CR6","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/cas.13979","volume":"110","author":"H Sudo","year":"2019","unstructured":"Sudo, H. et al. Therapeutic efficacy evaluation of radioimmunotherapy with (90) Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma. Cancer Sci. 110, 1653\u20131664. https:\/\/doi.org\/10.1111\/cas.13979 (2019).","journal-title":"Cancer Sci."},{"key":"76778_CR7","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1158\/1078-0432.Ccr-18-3476","volume":"25","author":"UB Hagemann","year":"2019","unstructured":"Hagemann, U. B. et al. Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Clin. Cancer Res. 25, 4723\u20134734. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3476 (2019).","journal-title":"Clin. Cancer Res."},{"key":"76778_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120633","author":"A Joshkon","year":"2020","unstructured":"Joshkon, A. et al. Role of CD146 (MCAM) in physiological and pathological angiogenesis-contribution of new antibodies for therapy. Biomedicineshttps:\/\/doi.org\/10.3390\/biomedicines8120633 (2020).","journal-title":"Biomedicines"},{"key":"76778_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41392-020-00259-8","volume":"5","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduct. Target Ther. 5, 148. https:\/\/doi.org\/10.1038\/s41392-020-00259-8 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"76778_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/0008-5472.Can-08-1363","volume":"69","author":"S Bidlingmaier","year":"2009","unstructured":"Bidlingmaier, S. et al. Identification of MCAM\/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 69, 1570\u20131577. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-1363 (2009).","journal-title":"Cancer Res."},{"key":"76778_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12094-013-1057-6","volume":"16","author":"X Zhang","year":"2014","unstructured":"Zhang, X. et al. MCAM expression is associated with poor prognosis in non-small cell lung cancer. Clin. Transl. Oncol. 16, 178\u2013183. https:\/\/doi.org\/10.1007\/s12094-013-1057-6 (2014).","journal-title":"Clin. Transl. Oncol."},{"key":"76778_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s13277-012-0417-0","volume":"33","author":"Z Wu","year":"2012","unstructured":"Wu, Z. et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour. Biol. 33, 1619\u20131628. https:\/\/doi.org\/10.1007\/s13277-012-0417-0 (2012).","journal-title":"Tumour. Biol."},{"key":"76778_CR13","doi-asserted-by":"publisher","first-page":"20220085","DOI":"10.1002\/VIW.20220085","volume":"4","author":"Q Yang","year":"2023","unstructured":"Yang, Q. et al. CD146-targeted nuclear medicine imaging in cancer: State of the art. VIEW 4, 20220085. https:\/\/doi.org\/10.1002\/VIW.20220085 (2023).","journal-title":"VIEW"},{"key":"76778_CR14","doi-asserted-by":"publisher","first-page":"e0165382","DOI":"10.1371\/journal.pone.0165382","volume":"11","author":"S Westrom","year":"2016","unstructured":"Westrom, S. et al. Evaluation of CD146 as target for radioimmunotherapy against osteosarcoma. PLoS One 11, e0165382. https:\/\/doi.org\/10.1371\/journal.pone.0165382 (2016).","journal-title":"PLoS One"},{"key":"76778_CR15","first-page":"5106","volume":"62","author":"L Mills","year":"2002","unstructured":"Mills, L. et al. Fully human antibodies to MCAM\/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62, 5106\u20135114 (2002).","journal-title":"Cancer Res"},{"key":"76778_CR16","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00259-016-3442-1","volume":"43","author":"H Sun","year":"2016","unstructured":"Sun, H. et al. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Eur. J. Nucl. Med. Mol. Imaging 43, 2169\u20132179. https:\/\/doi.org\/10.1007\/s00259-016-3442-1 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"76778_CR17","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1021\/acs.molpharmaceut.6b00372","volume":"13","author":"R Hernandez","year":"2016","unstructured":"Hernandez, R. et al. ImmunoPET imaging of CD146 expression in malignant brain tumors. Mol. Pharm. 13, 2563\u20132570. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00372 (2016).","journal-title":"Mol. Pharm."},{"key":"76778_CR18","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1021\/acs.molpharmaceut.7b00216","volume":"14","author":"CG England","year":"2017","unstructured":"England, C. G. et al. ImmunoPET imaging of CD146 in murine models of intrapulmonary metastasis of non-small cell lung cancer. Mol. Pharm. 14, 3239\u20133247. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00216 (2017).","journal-title":"Mol. Pharm."},{"key":"76778_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/antib6040017","author":"J Stalin","year":"2017","unstructured":"Stalin, J., Nollet, M., Dignat-George, F., Bardin, N. & Blot-Chabaud, M. Therapeutic and diagnostic antibodies to CD146: Thirty years of research on its potential for detection and treatment of tumors. Antibodies (Basel)https:\/\/doi.org\/10.3390\/antib6040017 (2017).","journal-title":"Antibodies (Basel)"},{"key":"76778_CR20","first-page":"6560","volume":"9","author":"EC McGary","year":"2003","unstructured":"McGary, E. C. et al. A fully human antimelanoma cellular adhesion Molecule\/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin. Cancer Res. 9, 6560\u20136566 (2003).","journal-title":"Clin. Cancer Res."},{"key":"76778_CR21","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3892\/ol.2017.5630","volume":"13","author":"X Ma","year":"2017","unstructured":"Ma, X. et al. Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells. Oncol. Lett. 13, 1681\u20131687. https:\/\/doi.org\/10.3892\/ol.2017.5630 (2017).","journal-title":"Oncol. Lett."},{"key":"76778_CR22","doi-asserted-by":"publisher","first-page":"112283","DOI":"10.18632\/oncotarget.22736","volume":"8","author":"M Nollet","year":"2017","unstructured":"Nollet, M. et al. A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule. Oncotarget 8, 112283\u2013112296. https:\/\/doi.org\/10.18632\/oncotarget.22736 (2017).","journal-title":"Oncotarget"},{"key":"76778_CR23","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.7150\/thno.15568","volume":"6","author":"R Hernandez","year":"2016","unstructured":"Hernandez, R. et al. CD146-targeted immunoPET and NIRF imaging of hepatocellular carcinoma with a dual-labeled monoclonal antibody. Theranostics 6, 1918\u20131933. https:\/\/doi.org\/10.7150\/thno.15568 (2016).","journal-title":"Theranostics"},{"key":"76778_CR24","first-page":"1586","volume":"11","author":"CA Ferreira","year":"2021","unstructured":"Ferreira, C. A. et al. ImmunoPET of the differential expression of CD146 in breast cancer. Am. J. Cancer Res. 11, 1586\u20131599 (2021).","journal-title":"Am. J. Cancer Res."},{"issue":"18","key":"76778_CR25","doi-asserted-by":"publisher","first-page":"8614","DOI":"10.18632\/oncotarget.2345","volume":"5","author":"S Thomann","year":"2014","unstructured":"Thomann, S. et al. Selective targeting of liver cancer with the endothelial marker CD146. Oncotarget 5(18), 8614\u20138624. https:\/\/doi.org\/10.18632\/oncotarget.2345 (2014).","journal-title":"Oncotarget"},{"key":"76778_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12935-019-0969-9","volume":"19","author":"AM Olajuyin","year":"2019","unstructured":"Olajuyin, A. M., Olajuyin, A. K., Wang, Z., Zhao, X. & Zhang, X. CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target. Cancer Cell Int. 19, 247. https:\/\/doi.org\/10.1186\/s12935-019-0969-9 (2019).","journal-title":"Cancer Cell Int."},{"key":"76778_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00128071-200809050-00004","volume":"9","author":"M Zigler","year":"2008","unstructured":"Zigler, M., Villares, G. J., Lev, D. C., Melnikova, V. O. & Bar-Eli, M. Tumor immunotherapy in melanoma: Strategies for overcoming mechanisms of resistance and escape. Am. J. Clin. Dermatol. 9, 307\u2013311. https:\/\/doi.org\/10.2165\/00128071-200809050-00004 (2008).","journal-title":"Am. J. Clin. Dermatol."},{"key":"76778_CR28","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1038\/onc.2016.72","volume":"35","author":"S Nodomi","year":"2016","unstructured":"Nodomi, S. et al. CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor. Oncogene 35, 5317\u20135327. https:\/\/doi.org\/10.1038\/onc.2016.72 (2016).","journal-title":"Oncogene"},{"key":"76778_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1073\/pnas.1111053108","volume":"109","author":"Q Zeng","year":"2012","unstructured":"Zeng, Q. et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc. Nat. Acad. Sci. 109, 1127\u20131132. https:\/\/doi.org\/10.1073\/pnas.1111053108 (2012).","journal-title":"Proc. Nat. Acad. Sci."},{"key":"76778_CR30","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/modpathol.2010.134","volume":"23","author":"A Sato","year":"2010","unstructured":"Sato, A. et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod. Pathol. 23, 1458\u20131466. https:\/\/doi.org\/10.1038\/modpathol.2010.134 (2010).","journal-title":"Mod. Pathol."},{"key":"76778_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3934\/medsci.2015.3.228","volume":"2","author":"K Yong","year":"2015","unstructured":"Yong, K. & Brechbiel, M. Application of (212)Pb for targeted \u03b1-particle therapy (TAT): Pre-clinical and mechanistic understanding through to clinical translation. AIMS Med. Sci. 2, 228\u2013245. https:\/\/doi.org\/10.3934\/medsci.2015.3.228 (2015).","journal-title":"AIMS Med. Sci."},{"key":"76778_CR32","first-page":"166","volume":"52","author":"MW Brechbiel","year":"2008","unstructured":"Brechbiel, M. W. Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imaging 52, 166\u2013173 (2008).","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"76778_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010189","author":"KV Kokov","year":"2022","unstructured":"Kokov, K. V. et al. (212)Pb: Production approaches and targeted therapy applications. Pharmaceuticshttps:\/\/doi.org\/10.3390\/pharmaceutics14010189 (2022).","journal-title":"Pharmaceutics"},{"key":"76778_CR34","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2967\/jnumed.120.261016","volume":"62","author":"V Radchenko","year":"2021","unstructured":"Radchenko, V. et al. Production and supply of \u03b1-particle-emitting radionuclides for targeted \u03b1-therapy. J. Nucl. Med. 62, 1495\u20131503. https:\/\/doi.org\/10.2967\/jnumed.120.261016 (2021).","journal-title":"J. Nucl. Med."},{"key":"76778_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros, G. et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and dosimetry of \u03b1-particle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311\u2013328. https:\/\/doi.org\/10.2967\/jnumed.108.058651 (2010).","journal-title":"J. Nucl. Med."},{"key":"76778_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.5114\/jcb.2019.88138","volume":"11","author":"SR Bellia","year":"2019","unstructured":"Bellia, S. R. et al. Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. J. Contemp. Brachyther. 11, 449\u2013457. https:\/\/doi.org\/10.5114\/jcb.2019.88138 (2019).","journal-title":"J. Contemp. Brachyther."},{"key":"76778_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2967\/jnumed.119.227835","volume":"61","author":"CN Leung","year":"2020","unstructured":"Leung, C. N. et al. Dose-dependent growth delay of breast cancer xenografts in the bone marrow of mice treated with (223)Ra: The role of bystander effects and their potential for therapy. J. Nucl. Med. 61, 89\u201395. https:\/\/doi.org\/10.2967\/jnumed.119.227835 (2020).","journal-title":"J. Nucl. Med."},{"key":"76778_CR38","doi-asserted-by":"publisher","first-page":"e69613","DOI":"10.1371\/journal.pone.0069613","volume":"8","author":"V Boudousq","year":"2013","unstructured":"Boudousq, V. et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One 8, e69613. https:\/\/doi.org\/10.1371\/journal.pone.0069613 (2013).","journal-title":"PLoS One"},{"key":"76778_CR39","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/coc.0000000000000353","volume":"41","author":"RF Meredith","year":"2018","unstructured":"Meredith, R. F. et al. Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab. Am. J. Clin. Oncol. 41, 716\u2013721. https:\/\/doi.org\/10.1097\/coc.0000000000000353 (2018).","journal-title":"Am. J. Clin. Oncol."},{"key":"76778_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4161\/19420862.2014.985160","volume":"7","author":"DE Milenic","year":"2015","unstructured":"Milenic, D. E., Baidoo, K. E., Kim, Y. S. & Brechbiel, M. W. Evaluation of cetuximab as a candidate for targeted \u03b1-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs 7, 255\u2013264. https:\/\/doi.org\/10.4161\/19420862.2014.985160 (2015).","journal-title":"MAbs"},{"key":"76778_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.tranon.2017.04.004","volume":"10","author":"DE Milenic","year":"2017","unstructured":"Milenic, D. E., Baidoo, K. E., Kim, Y. S., Barkley, R. & Brechbiel, M. W. Targeted \u03b1-particle radiation therapy of HER1-positive disseminated intraperitoneal disease: An investigation of the human anti-EGFR monoclonal antibody, Panitumumab. Transl. Oncol. 10, 535\u2013545. https:\/\/doi.org\/10.1016\/j.tranon.2017.04.004 (2017).","journal-title":"Transl. Oncol."},{"key":"76778_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1089\/cbr.2018.2434","volume":"33","author":"DE Milenic","year":"2018","unstructured":"Milenic, D. E. et al. Exploration of a F(ab\u2019)(2) fragment as the targeting agent of \u03b1-radiation therapy: A Comparison of the therapeutic benefit of intraperitoneal and intravenous administered radioimmunotherapy. Cancer Biother. Radiopharm. 33, 182\u2013193. https:\/\/doi.org\/10.1089\/cbr.2018.2434 (2018).","journal-title":"Cancer Biother. Radiopharm."},{"key":"76778_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.nucmedbio.2017.01.003","volume":"47","author":"BB Kasten","year":"2017","unstructured":"Kasten, B. B. et al. B7\u2013H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl. Med. Biol. 47, 23\u201330. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.01.003 (2017).","journal-title":"Nucl. Med. Biol."},{"key":"76778_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nucmedbio.2017.12.004","volume":"58","author":"BB Kasten","year":"2018","unstructured":"Kasten, B. B. et al. (212)Pb-labeled B7\u2013H3-targeting antibody for pancreatic cancer therapy in mouse models. Nucl. Med. Biol. 58, 67\u201373. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.004 (2018).","journal-title":"Nucl. Med. Biol."},{"key":"76778_CR45","first-page":"114","volume":"57","author":"B Kasten","year":"2016","unstructured":"Kasten, B., Fan, J., Ferrone, S., Zinn, K. & Buchsbaum, D. Targeted radioimmunotherapy of triple negative breast cancer with CSPG4-specific 212Pb-labeled monoclonal antibody. J. Nucl. Med. 57, 114\u2013114 (2016).","journal-title":"J. Nucl. Med."},{"key":"76778_CR46","doi-asserted-by":"publisher","first-page":"e0230526","DOI":"10.1371\/journal.pone.0230526","volume":"15","author":"AF Maaland","year":"2020","unstructured":"Maaland, A. F. et al. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS One 15, e0230526. https:\/\/doi.org\/10.1371\/journal.pone.0230526 (2020).","journal-title":"PLoS One"},{"key":"76778_CR47","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2967\/jnumed.119.239491","volume":"61","author":"I Quelven","year":"2020","unstructured":"Quelven, I. et al. (212)Pb \u03b1-radioimmunotherapy targeting CD38 in multiple myeloma: A preclinical study. J. Nucl. Med. 61, 1058\u20131065. https:\/\/doi.org\/10.2967\/jnumed.119.239491 (2020).","journal-title":"J. Nucl. Med."},{"key":"76778_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1874471013666200511000532","volume":"13","author":"VY Stenberg","year":"2020","unstructured":"Stenberg, V. Y., Juzeniene, A., Bruland, \u00d8. S. & Larsen, R. H. In situ generated (212)Pb-PSMA ligand in a (224)Ra-solution for dual targeting of prostate cancer sclerotic stroma and PSMA-positive cells. Curr. Radiopharm. 13, 130\u2013141. https:\/\/doi.org\/10.2174\/1874471013666200511000532 (2020).","journal-title":"Curr. Radiopharm."},{"key":"76778_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jlcr.3825","volume":"63","author":"VY Stenberg","year":"2020","unstructured":"Stenberg, V. Y. et al. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [(212) Pb]Pb-NG001 for prostate cancer. J. Labelled Comp. Radiopharm. 63, 129\u2013143. https:\/\/doi.org\/10.1002\/jlcr.3825 (2020).","journal-title":"J. Labelled Comp. Radiopharm."},{"key":"76778_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094815","author":"VY Stenberg","year":"2021","unstructured":"Stenberg, V. Y. et al. Evaluation of the PSMA-binding ligand (212)Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int. J. Mol. Sci.https:\/\/doi.org\/10.3390\/ijms22094815 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"76778_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112784","author":"VY Stenberg","year":"2022","unstructured":"Stenberg, V. Y. et al. Factors influencing the therapeutic efficacy of the PSMA targeting radioligand (212)Pb-NG001. Cancers (Basel)https:\/\/doi.org\/10.3390\/cancers14112784 (2022).","journal-title":"Cancers (Basel)"},{"key":"76778_CR52","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/cyto.a.20435","volume":"71A","author":"ML Conrad","year":"2007","unstructured":"Conrad, M. L., Davis, W. C. & Koop, B. F. TCR and CD3 antibody cross-reactivity in 44 species. Cytometry Part A 71A, 925\u2013933. https:\/\/doi.org\/10.1002\/cyto.a.20435 (2007).","journal-title":"Cytometry Part A"},{"key":"76778_CR53","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.nucmedbio.2013.01.010","volume":"40","author":"KE Baidoo","year":"2013","unstructured":"Baidoo, K. E., Milenic, D. E. & Brechbiel, M. W. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl. Med. Biol. 40, 592\u2013599. https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.01.010 (2013).","journal-title":"Nucl. Med. Biol."},{"key":"76778_CR54","doi-asserted-by":"publisher","first-page":"e221490","DOI":"10.1001\/jamanetworkopen.2022.1490","volume":"5","author":"T Meirson","year":"2022","unstructured":"Meirson, T. et al. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open 5, e221490. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.1490 (2022).","journal-title":"JAMA Netw Open"},{"key":"76778_CR55","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","volume":"19","author":"SG Gray","year":"2024","unstructured":"Gray, S. G., Meirson, T. & Mutti, L. Based on the real-world results from Australia, Immunotherapy is not a good option for patients with mesothelioma. J. Thorac. Oncol. 19, 541\u2013546. https:\/\/doi.org\/10.1016\/j.jtho.2024.01.016 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"76778_CR56","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/ijn.S186344","volume":"14","author":"E Cova","year":"2019","unstructured":"Cova, E. et al. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Int. J. Nanomed. 14, 773\u2013785. https:\/\/doi.org\/10.2147\/ijn.S186344 (2019).","journal-title":"Int. J. Nanomed."},{"key":"76778_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.04.005","volume":"51","author":"S Westrom","year":"2017","unstructured":"Westrom, S., Generalov, R., Bonsdorff, T. B. & Larsen, R. H. Preparation of (212)Pb-labeled monoclonal antibody using a novel (224)Ra-based generator solution. Nucl. Med. Biol. 51, 1\u20139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.04.005 (2017).","journal-title":"Nucl. Med. Biol."},{"key":"76778_CR58","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1039\/c0dt01387k","volume":"40","author":"K Yong","year":"2011","unstructured":"Yong, K. & Brechbiel, M. W. Towards translation of 212Pb as a clinical therapeutic; getting the lead in!. Dalton Trans. 40, 6068\u20136076. https:\/\/doi.org\/10.1039\/c0dt01387k (2011).","journal-title":"Dalton Trans."},{"key":"76778_CR59","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2967\/jnumed.114.143842","volume":"55","author":"R Meredith","year":"2014","unstructured":"Meredith, R. et al. Dose escalation and dosimetry of first-in-human \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab. J. Nucl. Med. 55, 1636\u20131642. https:\/\/doi.org\/10.2967\/jnumed.114.143842 (2014).","journal-title":"J. Nucl. Med."},{"key":"76778_CR60","unstructured":"B\u00f8nsdorff, T. & Larsen, R. H. Monoclonal antibody and derivatives. PCT\/EP2014\/070395 (2015)."},{"key":"76778_CR61","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(SICI)1097-0320(19970401)27:4<358::AID-CYTO7>3.0.CO;2-8","volume":"27","author":"M Poot","year":"1997","unstructured":"Poot, M., Gibson, L. L. & Singer, V. L. Detection of apoptosis in live cells by MitoTracker\u2122 Red CMXRos and SYTO dye flow cytometry. Cytometry 27, 358\u2013364 (1997).","journal-title":"Cytometry"},{"key":"76778_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0022-1759(99)00116-7","volume":"229","author":"PJ Smith","year":"1999","unstructured":"Smith, P. J., Wiltshire, M., Davies, S., Patterson, L. H. & Hoy, T. A novel cell permeant and far red-fluorescing DNA probe, DRAQ5, for blood cell discrimination by flow cytometry. J. Immunol. Methods 229, 131\u2013139. https:\/\/doi.org\/10.1016\/s0022-1759(99)00116-7 (1999).","journal-title":"J. Immunol. Methods"},{"key":"76778_CR63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221941","author":"W He","year":"2023","unstructured":"He, W. et al. Intracellular trafficking of HLA-E and its regulation. J. Exp. Med.https:\/\/doi.org\/10.1084\/jem.20221941 (2023).","journal-title":"J. Exp. Med."},{"key":"76778_CR64","doi-asserted-by":"publisher","first-page":"8390","DOI":"10.1038\/ncomms9390","volume":"6","author":"J-R Lin","year":"2015","unstructured":"Lin, J.-R., Fallahi-Sichani, M. & Sorger, P. K. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat. Commun. 6, 8390. https:\/\/doi.org\/10.1038\/ncomms9390 (2015).","journal-title":"Nat. Commun."},{"key":"76778_CR65","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot099143","author":"JB Fishman","year":"2019","unstructured":"Fishman, J. B. & Berg, E. A. Protein A and Protein G purification of antibodies. Cold Spring Harb Protochttps:\/\/doi.org\/10.1101\/pdb.prot099143 (2019).","journal-title":"Cold Spring Harb Protoc"},{"key":"76778_CR66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2967\/jnumed.122.264009","volume":"64","author":"RG Li","year":"2023","unstructured":"Li, R. G., Stenberg, V. Y. & Larsen, R. H. An experimental generator for production of high-purity (212)Pb for use in radiopharmaceuticals. J. Nucl. Med. 64, 173\u2013176. https:\/\/doi.org\/10.2967\/jnumed.122.264009 (2023).","journal-title":"J. Nucl. Med."},{"key":"76778_CR67","doi-asserted-by":"publisher","first-page":"109362","DOI":"10.1016\/j.apradiso.2020.109362","volume":"166","author":"E Napoli","year":"2020","unstructured":"Napoli, E. et al. Calibration of sodium iodide detectors and reentrant ionization chambers for (212)Pb activity in different geometries by HPGe activity determined samples. Appl. Radiat. Isot. 166, 109362. https:\/\/doi.org\/10.1016\/j.apradiso.2020.109362 (2020).","journal-title":"Appl. Radiat. Isot."},{"key":"76778_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ijc.2910380107","volume":"38","author":"O Fodstad","year":"1986","unstructured":"Fodstad, O. et al. Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int. J. Cancer 38, 33\u201340. https:\/\/doi.org\/10.1002\/ijc.2910380107 (1986).","journal-title":"Int. J. Cancer"},{"key":"76778_CR69","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ijrobp.2010.08.038","volume":"79","author":"H Heyerdahl","year":"2011","unstructured":"Heyerdahl, H., Krogh, C., Borreb\u00e6k, J., Larsen, \u00c5. & Dahle, J. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab. Int. J. Radiat. Oncol. Biol. Phys. 79, 563\u2013570. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.038 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"76778_CR70","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.nds.2007.07.001","volume":"108","author":"MJ Martin","year":"2007","unstructured":"Martin, M. J. Nuclear data sheets for A = 208. Nuclear Data Sheets 108, 1583\u20131806. https:\/\/doi.org\/10.1016\/j.nds.2007.07.001 (2007).","journal-title":"Nuclear Data Sheets"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76778-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T09:17:46Z","timestamp":1730193466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76778-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76778"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76778-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following conflicts of interest: K.L., R.G.L., S.M.D., T.B.B., and R.W. are employed at the privately held Norwegian company Oncoinvent A.S. K.L., R.G.L., M.M.M. and T.B.B. own stock in Oncoinvent ASA. Oncoinvent ASA hold intellectual proprietary rights PCT\/EP2014\/070395 in presented techology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental procedures involving animals were approved by the Institutional Committee on Research Animal Care (Department of Comparative Medicine, Oslo University Hospital, Norway) and the Norwegian Food Safety Authority. The animal experiments were approved under project number 23766 on 21 September 2020. The animals were treated in accordance with institutional, national, and EU regulations on the use of research animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"25941"}}